The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection
The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection
复制标题
DOI：
10.1016/j.vaccine.2005.08.061
复制
发表时间：
2006-01-30
期刊：
影响因子：
5.5
通讯作者：
Fiers, W
中科院分区：
文献类型：
--
作者：
De Filette, M;Ramne, A;Fiers, W
粘液瘤疫苗接种需要有效和安全的佐剂。我们已经评估了用于针对流感的粘膜疫苗接种的无毒佐剂CTA 1-DD。CTA 1-DD含有霍乱毒素（CT）的酶活性CTA 1亚基，与编码金黄色葡萄球菌蛋白A D片段二聚体的基因遗传融合。CTA 1-DD仅与免疫系统的Ig受体携带细胞结合。鼻腔给药通用流感疫苗M2 e-HBc与CTA 1-DD的组合完全保护小鼠免受潜在致死性感染，并显著降低发病率。用M2 e-HBc + CTA 1-DD免疫的小鼠的血清揭示了与增强的Th 1型免疫一致的IgG亚类谱。当疫苗经腹膜内给药时，佐剂提高了循环中的M2 e抗体滴度，但没有显著降低发病率。(c)2005爱思唯尔有限公司保留所有权利。
Mucosal vaccination requires effective and safe adjuvants. We have evaluated the non-toxic adjuvant CTA1-DD for mucosal vaccination against influenza. CTA1-DD contain, the enzymatically active CTA1 subunit of cholera toxin (CT) genetically fused to a gene encoding a dimer of the D-fragment from Staphylococcus aureus protein A. CTA1-DD only binds to Ig-receptor carrying cells of the immune system. Nasal administration of the universal influenza vaccine M2e-HBc in combination with CTA1-DD completely protected mice from a potentially lethal infection and significantly reduced morbidity. Sera of mice immunized with M2e-HBc + CTA1-DD revealed IgG subclass profiles consistent with an enhanced Th1-type immunity. When the vaccine was administered intraperitoneally, the adjuvant improved the M2e antibody titer in circulation, but did not significantly reduce the morbidity. (c) 2005 Elsevier Ltd. All rights reserved.